Regulatory Scrutiny Clouds Hims & Hers’ Entry into Weight-Loss Drug Market
06.02.2026 - 14:18:04
The recent foray by telehealth company Hims & Hers into the lucrative weight-loss medication sector has hit an early regulatory snag, casting doubt on what was anticipated to be a significant new revenue stream and sending its shares lower.
On Thursday, the company launched a compounded, capsule-based oral version of semaglutide. Priced aggressively at $49 for the first month and approximately $99 per month thereafter, the offering was positioned well below the cost of branded alternatives like Novo Nordisk’s Wegovy. The strategy aimed to capture market share rapidly by appealing to a broader, price-sensitive audience. The initial market reaction was notably negative for the industry’s established Read more...
@ boerse-global.de | US4330001060 REGULATORY
